Warning letter
HomeChoice Partners, Inc.: warning letter of Apr 9, 2020
FDA warning letter 606962 · Division of Pharmaceutical Quality Operations II
Key facts
| Reference number | 606962 |
|---|---|
| Company | HomeChoice Partners, Inc. |
| Subject | Drug/Prepared, Packed or Held Under Insanitary Conditions/Adulterated |
| Issue date | Apr 9, 2020 |
| Posted date | Apr 14, 2020 |
| Issuing office | Division of Pharmaceutical Quality Operations II |
| Product type | Drugs |
| Inspection city | Augusta |
| Inspection ZIP | 30901 |
| Inspection start date | Aug 13, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: